natgillin/translations-raw huggingface dataset:
The reaction was conducted at continuous stirring (250 to 300 rev./min.) for about 10 to 15 minutes. After the performed reaction the yielded granulate was subjected to sieving (sieves of ⌀ 2 mm and ⌀ 5 mm). 
Reakcija, odnosno proces, odvija se uz stalno miješanje (250 do 300 okretaja u minuti), tijekom pribl. 10 do 15 minuta, Po završetku procesa granulat nastao miješanjem odvodi se na sita D215 mm.
A station for heating a plurality of portions of ends of pipes made of thermoplastic material, comprising: 
Stanica za zagrijavanje velikog broja dijelova (2) krajeva cijevi (3) izrađenih od termoplastičnog materijala, koja sadrži:
Most preferably citrate buffer and carbonate buffers are excluded and the sole buffering agents are phosphate salts. 
Najpoželjnije, citratni pufer i karbonatni puferi su isključeni i jedina puferujuća sredstva su fosfatne soli.
a resin supplying device connected to the injection nozzle and configured for supplying synthetic resin at a liquid state to the injection nozzle. 
uređaj za dostavu smole (18), spojen s injekcijskom mlaznicom (15) i konfiguriran za dostavu sintetske smole u tekućem stanju u injekcijsku mlaznicu (15), naznačen time što uređaj dodatno ima:
and Z6 are either taken together to form an oxo group at the carbon atom to which they are attached; or Z5 and Z6 are each independently selected from the group consisting of H, —C1-6alkyl, —OT1 and —N(T2)(T3); 
2? i Z ili su uzeti zajedno kako bi formirali okso skupinu na ugljikovom atomu na koji su vezani; ili 2 i Z* su svaki neovisno odabrani iz skupine koju čine H, -C, galkil, -OT! i -N(T?X(T?);
ENHANCED PLASTIC NET BAG, as per claims 1 to 7, characterized by the fact that the laminar strip (5) forms a handle to hold and carry the bag, since the welds (6 and 7) of this laminar element with the tubular mesh body of the bag are sufficiently resistant. 
Plastična mrežasta vrećica, prema zahtjevima 1 do 7, naznačena time da laminarna traka (5) oblikuje ručke za držanje i nošenje vrećice, budući da zavari (6 i 7) navedenog laminarnog elementa s cjevastim tijelom mreže vrećice imaju dovoljnu čvrstoću.
causing the injection material to flow from the side wall grooves as far as into the groove parts via the material of the material webs, 
- - poticanje da injekcijski materijal protječe od bočnih utora (16) sve u utorne dijelove (17, 18) preko materijala iz mreža materijala (5),
The preferred fuel elements employed herein are primarily formed of a carbonaceous material. 
Poželjno se gorivi elementi koji se ovdje koriste primarno formiraju od ugljičnog materijala.
The trial looked at odor-related adverse events seen with standard free base formulation compared to enteric coated free base and enteric coated hydrochloride salt. 
Pokus je promatrao štetne događaje povezane s mirisom, primijećene kod standardnog pripravka slobodne baze, u usporedbi s enterički obloženom slobodnom bazom i enterički obloženom hidrokloridnom soli.
withdrawing and re-circulating at least part of said colloidal suspension from said milling chamber (4; 4A; 4B; 4C)to said agitated chamber. 
- < povlačenje 1 re-cirkulaciju najmanje dijela navedene koloidne suspenzije iz navedene komore za mljevenje (4; 4A; 4B; 4C) u navedenu komoru za miješanje.
The method of claim 2, wherein a reference picture index of the temporal merge candidate is set as 0. 
Postupak prema Zahtjevu 1, gdje se indeks referentne slike kandidata za vremensko spajanje postavlja na nulu.
The method of claim 14, wherein the stitches are sealed by applying a tape of impermeable material over the longitudinal edges. 
Postupak prema zahtjevu 14, naznačen time da se šavovi spajaju uz postavljanje trake od nepropusnog materijala preko uzdužnih rubova, t>&
The method includes a step of heating and mixing the combination of the gum and sugar component in water, ensuring a thoroughly mixed, homogenous mass is obtained. 
Postupak obuhvaća korak zagrijavanja 1 mješanja kombinacije gume i šećerne komponente u vodi, koji osigurava osnovnu izmješanu homogenu masu.
Accordingly, in another embodiment of the pharmaceutical methods of the invention, said Philadelphia chromosome positive or negative acute lymphoblastic leukemia (ALL) is refractory and/or relapsed Philadelphia chromosome positive or negative ALL. 
Konstrukt namijenjen upotrebi u skladu s patentnim zahtjevom 1 ili 2, naznačen time što je navedena akutna limfoblastična leukemija (ALL) refrakterna i/ili recidiv ALL.
A compound for use according to claim 18 wherein the agent for treatment of hypertension is an angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker, diuretic, beta-blocker, or calcium channel blocker. 
Spoj za uporabu prema zahtjevu 18, naznačen time, da sredstvo za liječenje hipertenzije je inhibitor enzima za pretvaranje angiotenzina, blokator receptora angiotenzina II, diuretik, beta-blokator, ili blokator kanala kalcija.
According to one embodiment of the present invention, the solids content of the coating composition is in the range from 5 wt.-% to 75 wt.-%, preferably from 20 to 67 wt.-%, more preferably from 30 to 65 wt.-%, and most preferably from 50 to 62 wt.-%, based on the total weight of the composition. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time da tekući pripravak za obradu sadrži kiselinu u količini od 0.1 do 100 mas. %, na temelju ukupne mase tekućeg pripravka za obradu, poželjno u količini od 1 do 80 mas. %, poželjnije u količini od 5 do 60 mas. %, te najpoželjnije u količini od 10 do 50 mas. %.
A method of producing a solid amorphous dispersion of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one comprising: 
Postupak proizvodnje krute amorfne disperzije 4-[3-(4-ciklopropankarbonil-piperazin-1-karbonil)-4-fluoro-benzil]2H-ftalazin-1-ona naznačen time da sadrži korake:
The mixture was hydrogenated for 72h at 3 bar H2. 
Smjesa se hidrogenizira kroz 72 sata pri tlaku od 3 bara H2.
The method of claim 1, wherein the mRNA comprises at least one modification that enhances the stability of the mRNA relative to its unmodified counterpart. 
Sastav za upotrebu prema bilo kojem od patentnih zahtjeva 1-4, gdje RNA molekula sadrži: najmanje jednu preinaku koja osigurava stabilnost molekule RNA;
A light source as claimed in claim 1, wherein the Faraday cage is of or includes a thin layer of conductive, transparent material and/or a mesh of conductive wire and/or reticular metal sheet. 
Svjetlosni izvor u skladu s bilo kojim prethodnim patentnim zahtjevom, naznačen time, da je Faradayev kavez izrađen od ili uključuje tanki sloj provodljivog, prozirnog materijala i/ili mrežicu od provodljive žice i/ili retikulirani metalni lim.
a plurality of water spray sources positioned to spray water over the sliding surface; wherein the plurality of water spray sources are positioned to provide a flow of water to impact a vehicle, the vehicle having a bottom surface sliding on the sliding surface and water impact surfaces spaced along opposite sides of the vehicle body; 
pri čemu je mnoštvo izvora za raspršivanje vode smješteno tako da osigurava strujanje vode za udaranje u vozilo, naznačen time što vozilo ima donju površinu koja klizi po kliznoj površini i površine za udaranje vode (34) razmaknute na suprotnim stranama (16) tijela vozila; i pri čemu je mnoštvo izvora za raspršivanje vode prilagođenih tako da utječu na klizno gibanje vozila.
The multi-specific fusion protein of claim 1, wherein the CD86 binding domain is a Fab, scFv, a domain antibody, or a heavy chain-only antibody specific for CD86, preferably wherein the CD86 binding domain comprises light and heavy chain variable domains of FUN1 anti-CD86 antibody or a humanized variant thereof, more preferably wherein the CD86 binding domain comprises amino acids 1-258 of SEQ ID NO: 187 or 237. 
Multispecifični fuzijski protein u skladu s patentnim zahtjevom 1, naznačen time što je domena za vezanje s CD86 Fab, scFv, domensko protutijelo, ili protutijelo samo s teškim lancem specifično za CD86, po mogućnosti gdje domena za vezanje s CD86 sadrži varijabilne domene lakog i teškog lanca protutijela FUN1 protiv CD86 ili njegove humanizirane varijante, poželjnije gdje domena za vezanje s CD86 sadrži aminokiseline 1-258 SEQ ID NO: 187 ili 237.
Ar1 is a 5- or 6-membered heteroaryl group selected from furanyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, pyridinyl, pyridazinyl, pyrimidinyl and pyrazinyl, wherein the phenyl or heteroaryl groups are optionally substituted by one or more substituents independently selected from fluoro, chloro, CN, C3-C7cydoalkyl, -O(C1-C4alkyl) or C1-C6alkyl, the latter two groups being optionally substituted by one or more fluoro atoms; and Ar2 is a 5- or 6-membered heteroaryl group selected from pyrrolyl, furanyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, pyridinyl, pyridazinyl, pyrimidinyl and pyrazinyl, wherein the phenyl or heteroaryl groups are optionally substituted by one or more substituents independently selected from fluoro, chloro, CN, C3-C7cycloalkyl, -O(C1-C4alkyl) or C1-C6alkyl, the latter two groups being optionally substituted by one or more fluoro atoms. 
Ar1 je 5- ili 6-eročlana heteroarilna skupina izabrana između furanil, tienil, oksazolil, tiazolil, imidazolil, pirazolil, izoksazolil, izotiazolil, piridinil, piridazinil, pirimidinil i pirazinil, gdje su fenil ili heteroarilne skupine po izboru supstituirane jednim ili više supstituenata nezavisno izabranih između fluor, klor, CN, C3-C7cikloalkil, -O(C1-C4alkil) ili C1-C6alkil, zadnje dvije skupine su po izboru supstituirane jednim ili više atoma fluora; i Ar2 je 5- ili 6-eročlana heteroarilna skupina izabrana između pirolil, furanil, tienil, oksazolil, tiazolil, imidazolil, pirazolil, izoksazolil, izotiazolil, piridinil, piridazinil, pirimidinil i pirazinil, gdje su fenil ili heteroarilne skupine po izboru supstituirane jednim ili više supstituenata nezavisno izabranih između fluor, klor, CN, C3-C7cikloalkil, -O(C1-C4alkil) ili C1-C6alkil, zadnje dvije skupine su po izboru supstituirane jednim ili više atoma fluora.;2.
The method of claim 1, wherein the conduit (52) further comprises a shut down valve (410). 
Postupak prema zahtjevu 8, naznačen time da vod (52) dodatno sadrži ventil za isključivanje (410) i/ili sustav za brzo otpuštanje (340).
A process for the preparation of a compound of formula I according to claim 1, which comprises: 
Postupak priprave spoja formule I u skladu s patentnim zahtjevom 1, naznačen time, da se isti sastoji od:
The method of claim 1, wherein in the site mapped to the number URL address at least one user interface is deleted, edited, generated, moved, rearranged, and resized in a drag & drop manner. 
Metoda iz patentnog zahtjeva 1, gdje je u internet stranica koja je mapirana do URL adrese sa brojem najmanje jedno korisničko sučelje je obrisano, uređeno, generirano, pomaknuto, preraspoređeno, ili mu je promijenjena veličina na povuci i pusti (drag & drop) način.
Use of E 71, wherein the IL-23 antagonist binds to and inhibits the activity of IL-23p19 or IL23R. 
Uporaba u skladu sa zahtjevom 71, naznačena time, da se IL-23 antagonist veže na i inhibira djelovanje IL-23p19 ili IL-23R.
The term "isomeric purity" in the present context refers to the amount of 3,11b- cis- dihydrotetrabenazine present relative to the total amount or concentration of dihydrotetrabenazine of all isomeric forms. 
Izraz "izomerna čistoća" u prikazanom kontekstu se odnosi na prisutnu količinu 3,11b-cis-dihidrotetrabenazin Izomera A relativno prema ukupnoj količini ili koncentraciji dihidrotetrabenazina u svim izomernim oblicima.
Preferably the movable base 544 presses on one end of the spring 540. 
Injekcijski sklop u skladu s patentnim zahtjevom 4, naznačen time što kraj opruge stoji na pokretnom podnožju
An AAV vector comprising a gene of interest for use in a method for delivering said gene of interest to motor neurons or glial cells by intraperitoneal (i.p. 
HR P20140643 T1 PATENTNI ZAHTJEVI AAV vektor koji sadrži gen od interesa za uporabu u metodi za dostavu navedenog gena od interesa motoričkim neuronima ili glija stanicama intraperitonealnim (i.p.
One type of recoil damper system provides for the development of an elastic section in the rear part of the stock suitable for partially absorbing the recoil energy through deformation. 
Jedna vrsta sustava za prigušivanje trzanja predviđa razvoj elastične sekcije u stražnjem dijelu kundaka, koja elastična sekcija je prikladna za djelomično apsorbiranje energije trzanja kroz deformaciju.
A pharmaceutical composition comprising the isolated antibody or fragment of claim 9 and a pharmaceutically acceptable carrier. 
Farmaceutski sastav koji sadrži izolirano antitijelo ili fragment prema bilo kojem od prethodnih patentnih zahtjeva i farmaceutski prihvatljiv nosač.
converting Compound 10 to Compound 6; wherein "lower alkyl" means alkyl groups of 1 to 6 carbon atoms in the chain. 
(6) prevođenju Spoja 10 u Spoj 6; gdje "niži alkil" znači alkilne skupine s 1 do 6 atoma ugljika u lancu.
wherein the first fragment and the second fragment are separated by less than or exactly 5 amino acids in the primary structure, wherein the polypeptide elicits antibodies that neutralize both toxin A and toxin B, wherein the first proximal end is within a short repeat, the second proximal end is within a short repeat and the first proximal end and the second proximal end do not disrupt short repeat-long repeat-short repeat portions. 
drugi fragment ima drugi proksimalni kraj; i gdje je prvi proksimalni kraj unutar kratkog ponavljanja i drugi proksimalni kraj je unutar kratkog ponavljanja; i gdje su prvi fragment i drugi fragment jedan uz drugog, te gdje polipeptid izaziva protutijela koja neutraliziraju toksin A i toksin B.
A method for manufacturing a composition for treating or controlling post-operative ocular inflammation of the anterior segment of an eye, said inflammation resulting from a procedure selected from the group consisting of photorefractive keratectomy, cataract removal surgery, intraocular lens ("IOL") implantation, laser-assisted in situ keratomileusis ("LASIK"), conductive keratoplasty, and radial keratotomy; the method comprising: 
Postupak za proizvodnju pripravka za liječenje ili kontrolu post-operativne očne upale prednjeg segmenta oka, pri čemu je spomenuta upala rezultat procedure izabrane iz grupe koja se sastoji od fotorefraktivne keratektomije, operacije uklanjanja katarakta, umetanja intraokularnih leća (,,IOL"), in situ keratomileuze potpomognute laserom (»LASIK"), konduktivne keratoplastije, te radijalne keratotomije; naznačen time da sadrži:
The aqueous pharmaceutical suspension according to claim 7, Wherein the propylparaben, sodium propylparaben, or potassium propylparaben is, by weight/volume (g/100 mL), 0.027% to about 0.040%. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 7, naznačena time što propilparaben, natrij-propilparaben ili kalij-propilparaben iznosi, težinski/volumno (g/100 ml), 0,027 % do otprilike 0,040 %.
Likewise particularly preferably, the pharmaceutical compositions or vaccines according to the invention can be used for the treatment of cancer or tumour diseases, preferably selected from colon carcinomas, melanomas, renal carcinomas, lymphomas, acute myeloid leukaemia (AML), acute lymphoid leukaemia (ALL), chronic myeloid leukaemia (CML), chronic lymphocytic leukaemia (CLL), gastrointestinal tumours, pulmonary carcinomas, gliomas, thyroid tumours, mammary carcinomas, prostate tumours, hepatomas, various virus-induced tumours such as, for example, papilloma virus-induced carcinomas (e.g. 
RNA molekula prema zahtjevu 1 naznačena time da je za uporabu za liječenje kanceroznih bolesti, autoimune bolesti, alergija ili zaraznih bolesti, pri čemu su kancerozne bolesti poželjno odabrane iz skupine koja sadrži karcinom debelog crijeva, melanom, karcinom bubrega, limfom, akutnu mijeloidnu leukemiju (AML), akutnu limfoidnu leukemiju (ALL), kroničnu mijeloidnu leukemiju (CML), kroničnu limfocitnu leukemiju (CLL), gastrointestinalne tumore, karcinome pluća, gliome, tumore štitnjače, karcinome dojke, tumore prostate, hepatome, razne tumore uzrokovane virusima kao što su, na primjer, karcinomi uzrokovani papiloma virusom (npr.
A process for preparing a crystalline form (Form C) of N-(3-cyano-4-methyl-1 H -indol-7-yl)-3-cyanobenzenesulfonamide according to any one of claims 1 to 6, characterized in that a crystalline form of N-(3-cyano-4-methyl-1 H -indol-7-yl)-3-cyanobenzenesulfonamide hydrate are heated and stirred in water at 60-90°C. 
Postupak za pripravu kristalnog oblika (Oblik C) spoja N-(3-cijano-4-metil-1H-indol-7-il)-3-cijanobenzen-sulfonamida u skladu s bilo kojim patentnim zahtjevom 1 do 6, naznačen time, da se kristalni oblik spoja N-(3-cijano-4-metil-1H-indol-7-il)-3-cijanobenzen-sulfonamid hidrata zagrijava i miješa u vodi na 60-90 °C.
Material is transferred from this tank into sterile vials. 
Materijal je prenesen iz ovog tanka u sterilne bočice.
The method of claim 3 wherein the step of assigning sequence tags to corresponding chromosome portions allows one mismatch. 
Postupak prema zahtjevu 1, naznačen time da korak dodjeljivanja obilježavajućih sekvenci odgovarajućim dijelovima kromosoma dozvoljava jedno neslaganje.
The cells were disrupted by homogenization to facilitate isolation of the IL-2 inclusion bodies. 
Stanice su razorene pomoću homogenizacije da se olakša izolacija IL-2 inkluzijskih tijela.
A pyrethroid or pyrethrin pediculicide for use in a method of treatment of a human subject to combat infestation by multicellular ectoparasites with exoskeletons, which method comprises topically applying to said subject a first and a second pediculicide, said first pediculicide being a carbamate or organophosphate pediculicide and said second pediculicide being a pyrethroid or pyrethrin pediculicide, characterized in that said second pediculicide is applied between 15 minutes and 12 hours after the application of said first pediculicide, and wherein the two pediculicides are applied as a composition for topical application in the form of a solution, a cream, a gel, a cream rinse, a dispersion, a powder, a lotion, a spray or an unguent, with at least one of the compositions being a shampoo or a cream rinse. 
PATENTNI ZAHTJEVI Piretroidni ili piretrinski pedikulicid, namijenjen upotrebi u postupku liječenja ljudskog subjekta radi borbe protiv infestacije višestaničnim ektoparazitima s egzoskeletom, gdje se navedeni postupak sastoji u topikalnoj primjeni na navedenom subjektu prvog i drugog pedikulicida, gdje je navedeni prvi pedikulicid karbamatni ili organofosfatni pedikulicid, a navedeni drugi pedikulicid je piretroidni ili piretrinski pedikulicid, naznačen time što se navedeni drugi pedikulicid primijenjuje između 15 minuta i 12 sati nakon primjene navedenog prvog pedikulicida, te gdje se ta dva pedikulicida primijenjuje u obliku pripravka za topikalnu primjenu u obliku otopine, kreme, gela, regeneratora, disperzije, praška, losiona, spreja ili masti, gdje je najmanje jedan od pripravaka šampon ili regenerator.
One of the advantages of the present invention is that the high purity pravastatin is obtained without the need for purification by HPLC. 
Jedna od prednosti predstavljenog izuma jest ta da se pravastatin visoke čistoće dobiva bez potrebe pročišćavanja HPLC-om.
The composition according to claim 7, wherein the relative weight amounts (%, w/w) of trehalose, poloxamer 188, and N-Acetyl-cysteine are within the following ranges: trehalose to 10 
poloksamer 188 0.5 do 5 metionin 0.1 do 0.3, ili pri čemu su količine relativne težine (%, w/w) polokasmera 188 i metionina opcionalno unutar sljedećih raspona:
The starter culture according to claim 31 in the form of a concentrate. 
Starter kultura naznačena time da se dobiva pomoću postupka prema zahtjevu 1.
The composition according to any one of the preceding claims, wherein the calcium carbonate is present in an amount of at least 5.0 phr, preferably of at least 10 phr, more preferably of at least 15 phr and most preferably of 20 phr. 
Sastav prema bilo kojem od prethodnih zahtjeva, naznačen time da kalcij karbonat je prisutan u količini od barem 5.0 phr, poželjno barem 10 phr, još poželjnije barem 15 phr te najpoželjnije 20 phr.
be carried out by electronic control means (microprocessor etc.) 
provesti elektronskim mehanizmom za kontrolu (mikroprocesor itd.
M is O or CH2, Rb is selected from the group consisting of hydrogen, C1-4 alkyl, and aryl C1-4 alkyl 
Rb se bira iz skupine koju čine vodik, C1-4 alkil 1 aril C1-4 alkil;
a piperidyl group optionally substituted by C1-6 alkyl group(s), 
piperidil-skupina opcijski supstituirana s jednom ili više C1-6 alkil-skupina,
The use according to claim 20 or 21 or the method according to claim 22, wherein the cancer is selected from prostate cancer, non-small cell lung cancer, ovarian cancer, bladder cancer and gastric cancer. 
Uporaba prema zahtjevu 17, naznačena time da rak je odabran od raka prostate, raka pluća ne-malih stanica, raka jajnika, raka mjehura i raka želuca.
Use of an MMVF substrate formed from MMVF that has been made by a method according to any of claims 1 to 12, as (a) technical insulation or (b) for fire protection in an industrial or marine environment. 
Uporaba MMVF supstrata sukladno bilo kojem od zahtjeva 16 do 19, ili MMVF supstrat oblikovan od MMVE dobivenog postupkom sukladno bilo kojem od zahtjeva 1 do 9, kao (a) tehnička izolacija ili (b) za zaštitu od požara u industrijskom ili morskom okolišu.
to react with a compound of formula (B8): in which Y is a substituent which is displaced in a coupling reaction selected from a hydrogen atom, or a boronic acid group, or a boronic ester group; thereby giving a compound of formula (B), as defined in claim 1. 
(B8) u kojoj je Y supstituent koji je zamijenjen u reakciji spajanja odabran od vodikovog atoma, ili skupine boronske kiseline, ili skupine boronskog estera; te se tako dobiva spoj s formulom (B), kako je definirano u zahtjevu 1.
comminuting and classifying the calcium carbonate-containing rocks to a particle size in the range of from 1 mm to 250 mm, 
- - usitnjavanja i klasiranja stijena od kalcijevog karbonata na veličinu čestica u rasponu od 1 mm do 250 mm,
Preferably, reaction (N-reac) is done in a solvent (N-solv); solvent (N-solv) is selected from the group consisting of water, tert-butanol, isopropanol, acetonitrile, propionitrile, THF, methyl-THF, NMP, dioxane, 1,2-dimethoxyethane, dichloromethane, 1,2-dichloroethane, chloroform, toluene, benzene, chlorobenzene, hexane, cyclohexane, ethyl acetate, acetic acid, formic acid, trifluoroacetic acid and mixtures thereof; 
Postupak prema zahtjevu 1 ili 2, naznačen time da se reakcija (N-reak.) provodi u otapalu (N-otop.); otapalo (N-otap.) je izabrano iz skupine koja se sastoji od vode, terc-butanola, izopropanola, acetonitrila, propionitrila, THF, metil-THF, NMP, dioksana, 1,2-dimetoksietana, diklormetana, 1,2-dikloretana, kloroforma, toluola, benzola, klorbenzola, heksana, cikloheksana, etilnog estera octene kiseline, octene kiseline, mravlje kiseline, trifluoroctene kiseline i njihovih mješavina.
In some embodiments, the binding affinity of the mutant for the selected ligand is substantially the same or greater than the binding affinity of the parent for the selected ligand. 
Metoda iz Zahijeva 1-5 naznačena time da je sklonost vezanju mutacije na odabrani ligand u bitnome jednaka ili veća od sklonosti vezanju izvora na odabrani ligand.
Capsule according to claim 1, wherein the lower face (4) is permanently opened by internal perforation means (5) and by causing the lower face and perforation means to engage and the lower face being perforated accordingly. The capsule according to claim 1, wherein the valve means (15) are designed to block the flow path in an essentially airtight fashion. 
Kapsula u skladu s patentnim zahtjevom 1, naznačena time što u sebi nosi sredstvo (5) za probijanje donje površine (4) pod djelovanjem tlaka u odjeljku, gdje navedeni tlak uzrokuje da donja površina i sredstvo za probijanje (5) dođu u kontakt, čime dolazi do probijanja donje površine.